Intra-Cellular Therapies Stock Price, News & Analysis (NASDAQ:ITCI)

$19.65 -0.32 (-1.60 %)
(As of 02/21/2018 04:18 AM ET)
Previous Close$19.97
Today's Range$19.43 - $20.21
52-Week Range$7.85 - $22.67
Volume518,500 shs
Average Volume448,559 shs
Market Capitalization$1.07 billion
P/E Ratio-8.97
Dividend YieldN/A
Beta0.87

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ITCI
CUSIPN/A
Phone+1-212-9233344

Debt

Debt-to-Equity RatioN/A
Current Ratio28.09%
Quick Ratio28.09%

Price-To-Earnings

Trailing P/E Ratio-8.97260273972603
Forward P/E Ratio-9.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$330,000.00
Price / Sales3,249.99
Cash FlowN/A
Price / CashN/A
Book Value$8.68 per share
Price / Book2.26

Profitability

Trailing EPS($2.19)
Net Income$-116,420,000.00
Net Margins-28,038.35%
Return on Equity-27.40%
Return on Assets-26.31%

Miscellaneous

Employees42
Outstanding Shares54,580,000

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.00. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The company's revenue was up 675.0% compared to the same quarter last year. During the same period last year, the business posted ($0.70) EPS. View Intra-Cellular Therapies' Earnings History.

When will Intra-Cellular Therapies make its next earnings announcement?

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Intra-Cellular Therapies.

Where is Intra-Cellular Therapies' stock going? Where will Intra-Cellular Therapies' stock price be in 2018?

10 brokers have issued 12-month target prices for Intra-Cellular Therapies' shares. Their forecasts range from $12.00 to $36.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $27.44 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.

What are Wall Street analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:

  • 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (1/23/2018)
  • 2. SunTrust Banks, Inc. analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017)
  • 3. Cowen Inc analysts commented, "This AM, ITCI disclosed FDA had agreed lumateperone preclinical dog tox signals." (8/23/2017)

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decline in short interest in January. As of January 12th, there was short interest totalling 2,869,681 shares, a decline of 39.5% from the December 29th total of 4,746,634 shares. Based on an average trading volume of 660,729 shares, the days-to-cover ratio is currently 4.3 days. Currently, 6.5% of the shares of the stock are short sold.

Who are some of Intra-Cellular Therapies' key competitors?

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the folowing people:

  • Lawrence J. Hineline CPA, Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary (Age 60)
  • Andrew Satlin, Executive Vice President and Chief Medical Officer
  • Robert E. Davis Ph.D., Senior Vice President and Chief Scientific Officer (Age 66)
  • Michael I. Halstead, Senior Vice President, General Counsel, Secretary (Age 44)
  • Kimberly E. Vanover Ph.D., Senior Vice President, Clinical Development (Age 51)
  • Juan F. Sanchez M.D., Vice President - Corporate Communications (Age 44)
  • Sharon Mates Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 64)
  • Christopher D. Alafi Ph.D., Independent Director (Age 53)
  • Richard Alan Lerner M.D., Independent Director (Age 78)
  • Joel S. Marcus J.D. CPA, Independent Director (Age 69)

Who owns Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), Wasatch Advisors Inc. (3.53%), Millennium Management LLC (2.67%), Deutsche Bank AG (1.43%), Renaissance Technologies LLC (1.05%) and Geode Capital Management LLC (0.74%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Who sold Intra-Cellular Therapies stock? Who is selling Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Goldman Sachs Group Inc., Wasatch Advisors Inc., C WorldWide Group Holding A S, Wells Fargo & Company MN, Metropolitan Life Insurance Co. NY, Alliancebernstein L.P. and C M Bidwell & Associates Ltd.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Who bought Intra-Cellular Therapies stock? Who is buying Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Deutsche Bank AG, Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc. and TIAA CREF Investment Management LLC. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.

How do I buy Intra-Cellular Therapies stock?

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $19.65.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $1.07 billion and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-116,420,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Intra-Cellular Therapies employs 42 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 E 29th St, NEW YORK, NY 10016-8367, United States. The biopharmaceutical company can be reached via phone at +1-212-9233344.


MarketBeat Community Rating for Intra-Cellular Therapies (ITCI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  438
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intra-Cellular Therapies (NASDAQ:ITCI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.892.882.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.44$26.75$26.14$25.88
Price Target Upside: 67.45% upside79.53% upside78.33% upside62.74% upside

Intra-Cellular Therapies (NASDAQ:ITCI) Consensus Price Target History

Price Target History for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$33.00MediumView Rating Details
12/15/2017Canaccord GenuityInitiated CoverageBuy -> Buy$31.00HighView Rating Details
11/8/2017SunTrust BanksUpgradeHold -> BuyN/AView Rating Details
9/8/2017BTIG ResearchReiterated RatingBuy$36.00MediumView Rating Details
9/8/2017CowenReiterated RatingOutperform$20.00 -> $27.00MediumView Rating Details
9/7/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00 -> $33.00HighView Rating Details
8/24/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$24.00HighView Rating Details
8/23/2017Leerink SwannUpgradeMarket Perform -> OutperformHighView Rating Details
8/9/2017Cantor FitzgeraldReiterated RatingBuyHighView Rating Details
5/2/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralHighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Intra-Cellular Therapies (NASDAQ:ITCI) Earnings History and Estimates Chart

Earnings by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ ITCI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/8/2017Q3 2017($0.53)($0.53)$0.06 million$0.03 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.74)($0.41)$0.03 million$0.11 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.74)($0.62)$0.02 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.77)($0.64)$0.10 million$0.10 millionViewListenView Earnings Details
11/9/2016Q316($0.84)($0.70)$0.04 million$4.36 millionViewListenView Earnings Details
8/4/2016Q216($0.79)($0.71)$0.02 million$0.23 millionViewN/AView Earnings Details
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details
2/25/2016Q415($0.84)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details
11/5/2015Q315($0.66)($0.91)$0.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details
3/12/2015Q4 2014($0.49)($0.52)$0.07 millionViewN/AView Earnings Details
11/3/2014Q314($0.34)($0.22)$0.12 millionViewN/AView Earnings Details
8/12/2014Q214($0.24)($0.15)$0.22 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.17)$0.17 millionViewN/AView Earnings Details
3/26/2014($0.41)($0.36)$0.60 million$0.83 millionViewN/AView Earnings Details
11/5/2013Q3 2013($0.23)($0.42)$0.67 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Intra-Cellular Therapies (NASDAQ:ITCI) Earnings Estimates

2018 EPS Consensus Estimate: ($2.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.49)($0.49)($0.49)
Q2 20181($0.53)($0.53)($0.53)
Q3 20181($0.61)($0.61)($0.61)
Q4 20181($0.61)($0.61)($0.61)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.00%
Institutional Ownership Percentage: 76.93%
Insider Trades by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ ITCI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Lawrence J HinelineVPSell49,700$20.02$994,994.00View SEC Filing  
1/22/2018Michael HalsteadSVPSell25,500$18.03$459,765.00191View SEC Filing  
1/8/2018Kimberly E VanoverSVPSell772$17.46$13,479.1212,373View SEC Filing  
1/8/2018Sharon MatesChairmanSell6,604$17.48$115,437.921,088,707View SEC Filing  
1/5/2018Kimberly E VanoverSVPSell1,185$17.37$20,583.4526,803View SEC Filing  
1/5/2018Sharon MatesChairmanSell11,257$17.08$192,269.561,099,964View SEC Filing  
1/4/2018Lawrence J HinelineCFOSell3,192$15.67$50,018.6468,686View SEC Filing  
12/29/2017Christopher D AlafiDirectorBuy1,001$14.48$14,494.48View SEC Filing  
12/11/2017Richard A LernerDirectorSell7,000$15.09$105,630.008,621View SEC Filing  
12/5/2017Robert E DavisSVPSell650$15.00$9,750.0028,514View SEC Filing  
11/22/2017Christopher D AlafiDirectorBuy10,000$15.55$155,500.00744,466View SEC Filing  
10/30/2017Sharon MatesCEOSell18,750$15.75$295,312.501,107,457View SEC Filing  
10/2/2017Alafi Capital Co LlcMajor ShareholderBuy258,065$15.50$4,000,007.503,953,270View SEC Filing  
1/5/2017Lawrence J HinelineVPSell1,918$16.58$31,800.4463,389View SEC Filing  
1/5/2017Michael HalsteadSVPSell1,601$16.55$26,496.5521,506View SEC Filing  
1/5/2017Sharon MatesChairmanSell4,081$16.55$67,540.551,088,707View SEC Filing  
12/15/2016Kimberly E VanoverSVPSell9,375$15.23$142,781.255,000View SEC Filing  
12/7/2016Alafi Capital Co LlcMajor ShareholderBuy65,000$16.27$1,057,550.003,674,379View SEC Filing  
11/14/2016Christopher D AlafiDirectorBuy34,000$14.50$493,000.00730,529View SEC Filing  
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00728,828View SEC Filing  
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.0062,200View SEC Filing  
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.001,086,185View SEC Filing  
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.0018,722View SEC Filing  
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.0059,700View SEC Filing  
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intra-Cellular Therapies (NASDAQ ITCI) News Headlines

Source:
DateHeadline
Intra-Cellular Therapies Inc (ITCI) Receives Average Rating of "Buy" from AnalystsIntra-Cellular Therapies Inc (ITCI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 20 at 7:46 PM
Lawrence J. Hineline Sells 49,700 Shares of Intra-Cellular Therapies Inc (ITCI) StockLawrence J. Hineline Sells 49,700 Shares of Intra-Cellular Therapies Inc (ITCI) Stock
www.americanbankingnews.com - February 20 at 6:40 PM
Intra-Cellular Therapies (ITCI) Upgraded to Sell by BidaskClubIntra-Cellular Therapies (ITCI) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - February 19 at 3:56 PM
UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare ConferenceUPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 5:10 PM
Intra-Cellular Therapies (ITCI) Now Covered by Royal Bank of CanadaIntra-Cellular Therapies (ITCI) Now Covered by Royal Bank of Canada
www.americanbankingnews.com - February 11 at 3:24 PM
Intra-Cellular Therapies to Present at Upcoming Investor ConferencesIntra-Cellular Therapies to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:52 AM
Intra-Cellular Therapies (ITCI) Cut to "Strong Sell" at BidaskClubIntra-Cellular Therapies (ITCI) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - February 3 at 2:44 PM
Financial Contrast: Intra-Cellular Therapies (ITCI) and Mast Therapeutics (SVRA)Financial Contrast: Intra-Cellular Therapies (ITCI) and Mast Therapeutics (SVRA)
www.americanbankingnews.com - February 3 at 1:12 AM
Intra-Cellular Therapies Inc (ITCI) Short Interest UpdateIntra-Cellular Therapies Inc (ITCI) Short Interest Update
www.americanbankingnews.com - January 27 at 2:32 AM
Intra-Cellular Therapies Inc (ITCI) Given Consensus Recommendation of "Buy" by AnalystsIntra-Cellular Therapies Inc (ITCI) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 26 at 7:28 PM
Michael Halstead Sells 25,500 Shares of Intra-Cellular Therapies Inc (ITCI) StockMichael Halstead Sells 25,500 Shares of Intra-Cellular Therapies Inc (ITCI) Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Stock Review for Biotechs Investors -- Inovio Pharma, Insmed, Intra-Cellular Therapies, and Jazz PharmaStock Review for Biotech's Investors -- Inovio Pharma, Insmed, Intra-Cellular Therapies, and Jazz Pharma
www.bizjournals.com - January 22 at 9:22 AM
Intra-Cellular Therapies (ITCI) Upgraded by Zacks Investment Research to BuyIntra-Cellular Therapies (ITCI) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 20 at 12:33 PM
Investors Purchase High Volume of Intra-Cellular Therapies Put Options (ITCI)Investors Purchase High Volume of Intra-Cellular Therapies Put Options (ITCI)
www.americanbankingnews.com - January 19 at 3:10 AM
Intra-Cellular Therapies (ITCI) Lowered to "Hold" at Zacks Investment ResearchIntra-Cellular Therapies (ITCI) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 8:10 PM
Intra-Cellular Therapies (ITCI) Raised to Buy at Zacks Investment ResearchIntra-Cellular Therapies (ITCI) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - January 13 at 7:14 PM
Intra-Cellular Therapies Inc. (ITCI) Chairman Sharon Mates Sells 6,604 SharesIntra-Cellular Therapies Inc. (ITCI) Chairman Sharon Mates Sells 6,604 Shares
www.americanbankingnews.com - January 10 at 10:00 PM
Kimberly E. Vanover Sells 772 Shares of Intra-Cellular Therapies Inc. (ITCI) StockKimberly E. Vanover Sells 772 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock
www.americanbankingnews.com - January 10 at 10:00 PM
Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI - Business Wire (press release)Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI - Business Wire (press release)
www.businesswire.com - January 10 at 3:29 PM
Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCINewman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI
finance.yahoo.com - January 10 at 3:29 PM
Intra-Cellular Therapies Inc. (ITCI) to Post FY2019 Earnings of ($1.89) Per Share, Leerink Swann ForecastsIntra-Cellular Therapies Inc. (ITCI) to Post FY2019 Earnings of ($1.89) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 8 at 5:40 PM
BidaskClub Upgrades Intra-Cellular Therapies (ITCI) to SellBidaskClub Upgrades Intra-Cellular Therapies (ITCI) to Sell
www.americanbankingnews.com - January 6 at 12:48 AM
Lawrence J. Hineline Sells 3,192 Shares of Intra-Cellular Therapies Inc. (ITCI) StockLawrence J. Hineline Sells 3,192 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock
www.americanbankingnews.com - January 5 at 9:12 PM
Kimberly E. Vanover Sells 1,185 Shares of Intra-Cellular Therapies Inc. (ITCI) StockKimberly E. Vanover Sells 1,185 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock
www.americanbankingnews.com - January 5 at 9:12 PM
Intra-Cellular Therapies Inc. (ITCI) Chairman Sells $192,269.56 in StockIntra-Cellular Therapies Inc. (ITCI) Chairman Sells $192,269.56 in Stock
www.americanbankingnews.com - January 5 at 9:10 PM
Intra-Cellular Therapies Inc. (ITCI) Director Christopher D. Alafi Buys 1,001 SharesIntra-Cellular Therapies Inc. (ITCI) Director Christopher D. Alafi Buys 1,001 Shares
www.americanbankingnews.com - January 3 at 7:52 PM
Intra-Cellular Therapies to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Intra-Cellular Therapies to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 2 at 10:16 AM
Intra-Cellular Therapies (ITCI) Downgraded by ValuEngineIntra-Cellular Therapies (ITCI) Downgraded by ValuEngine
www.americanbankingnews.com - January 1 at 8:14 PM
Intra-Cellular Therapies Inc. (ITCI) Receives Consensus Rating of "Buy" from BrokeragesIntra-Cellular Therapies Inc. (ITCI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 1 at 7:40 PM
Intra-Cellular Therapies (ITCI) Downgraded by BidaskClubIntra-Cellular Therapies (ITCI) Downgraded by BidaskClub
www.americanbankingnews.com - December 30 at 2:54 PM
ETFs with exposure to Intra-Cellular Therapies, Inc. : December 28, 2017ETFs with exposure to Intra-Cellular Therapies, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:03 PM
Intra-Cellular Therapies, Inc. :ITCI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Intra-Cellular Therapies, Inc. :ITCI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:33 PM
Intra-Cellular Therapies, Inc. is trading above its 50 day moving average : ITCI-US : December 20, 2017Intra-Cellular Therapies, Inc. is trading above its 50 day moving average : ITCI-US : December 20, 2017
finance.yahoo.com - December 20 at 9:30 AM
Intra-Cellular Therapies (ITCI) Earns Buy Rating from Analysts at Canaccord GenuityIntra-Cellular Therapies (ITCI) Earns Buy Rating from Analysts at Canaccord Genuity
www.americanbankingnews.com - December 15 at 12:50 PM
Intra-Cellular Therapies Inc. (ITCI) Director Sells $105,630.00 in StockIntra-Cellular Therapies Inc. (ITCI) Director Sells $105,630.00 in Stock
www.americanbankingnews.com - December 13 at 6:40 PM
Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the ... - GlobeNewswire (press release)Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the ... - GlobeNewswire (press release)
globenewswire.com - December 8 at 3:28 PM
Intra-Cellular Therapies Inc. (ITCI) Receives Consensus Recommendation of "Buy" from AnalystsIntra-Cellular Therapies Inc. (ITCI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 7 at 7:44 PM
Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of NeuropsychopharmacologyIntra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology
finance.yahoo.com - December 7 at 9:53 AM
Intra-Cellular Therapies Inc. (ITCI) Director Buys $155,500.00 in StockIntra-Cellular Therapies Inc. (ITCI) Director Buys $155,500.00 in Stock
www.americanbankingnews.com - November 27 at 8:20 PM
Intra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare ConferenceIntra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 27 at 5:19 PM
Intra-Cellular Therapies (ITCI) Granted FDA Fast Track Designation for Lumateperone in Schizophrenia - StreetInsider.comIntra-Cellular Therapies (ITCI) Granted FDA Fast Track Designation for Lumateperone in Schizophrenia - StreetInsider.com
www.streetinsider.com - November 20 at 9:53 PM
Intra-Cellular Therapies (ITCI) Granted FDA Fast Track Designation for Lumateperone in SchizophreniaIntra-Cellular Therapies (ITCI) Granted FDA Fast Track Designation for Lumateperone in Schizophrenia
www.streetinsider.com - November 20 at 4:51 PM
Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of SchizophreniaIntra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia
finance.yahoo.com - November 20 at 4:51 PM
Should You Buy Intra-Cellular Therapies Inc (ITCI)?Should You Buy Intra-Cellular Therapies Inc (ITCI)?
finance.yahoo.com - November 20 at 4:51 PM
Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for ... - GlobeNewswire (press release)Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for ... - GlobeNewswire (press release)
globenewswire.com - November 15 at 3:23 AM
Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual MeetingIntra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual Meeting
finance.yahoo.com - November 15 at 3:23 AM
Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical OfficerIntra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer
finance.yahoo.com - November 13 at 4:24 PM
FY2017 EPS Estimates for Intra-Cellular Therapies Inc. Raised by Leerink Swann (ITCI)FY2017 EPS Estimates for Intra-Cellular Therapies Inc. Raised by Leerink Swann (ITCI)
www.americanbankingnews.com - November 13 at 3:00 AM
Intra-Cellular Therapies Inc. (ITCI) Receives Average Recommendation of "Buy" from AnalystsIntra-Cellular Therapies Inc. (ITCI) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 12 at 7:40 PM
Stocks To Watch: Intra-Cellular Therapies Sees RS Rating Rise To 88Stocks To Watch: Intra-Cellular Therapies Sees RS Rating Rise To 88
finance.yahoo.com - November 11 at 11:50 PM

SEC Filings

Intra-Cellular Therapies (NASDAQ:ITCI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intra-Cellular Therapies (NASDAQ:ITCI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intra-Cellular Therapies (NASDAQ ITCI) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.